



# Prescription Pharmaceuticals

Product / Family	Licensor	Indication / Potential Indication	Status in Territory	Territory Rights <sup>1</sup>
<b>Pain / Gastrointestinal</b>				
Movantik®	AstraZeneca	Opioid-induced constipation	Marketed in CAN and Approved in ISR	CAN, ISR
Probuphine™	Titan	Opioid addiction	Marketed	CAN
Ibsrela™	Ardelyx	IBS-C	Pending submission	CAN
Mytesi®	Jaguar	Anti-diarrheal	Pending submission	CAN, ISR
NeurAxon family	N/A	Acute migraine, pain and neurological disorders	Pre-Clinical – Phase 3	CAN, ISR, RUS, ZAF
Antibe family	Antibe	Chronic pain and inflammation	Pre-Clinical – Phase 2	CAN, ISR, RUS, ZAF
<b>Ophthalmic</b>				
AzaSite™	Akorn	Bacterial conjunctivitis	Approved	CAN
Iluvien®	Alimera	Diabetic macular edema	Approved	CAN
Netildex™	SIFI	Ocular inflammation	Submitted	CAN
<b>Women's Health</b>				
TX-004HR <sup>2</sup>	TherapeuticsMD	Moderate-to-severe dyspareunia	Pending submission	CAN, ISR
TX-001HR <sup>3</sup>	TherapeuticsMD	Moderate-to severe vasomotor symptoms due to menopause	Pending submission	CAN, ISR

<sup>1</sup> Legend: **CAN**: Canada, **ISR**: Israel, **ROM**: Romania, **RUS**: Russia, **ZAF**: Sub-Saharan Africa

<sup>2</sup> Marketed as **IMVEXXY** in the US

<sup>3</sup> Marketed as **BIJUVA** in the US



# Prescription Pharmaceuticals

Product / Family	Licensor	Indication / Potential Indication	Status in Territory	Territory Rights <sup>1</sup>
<b>Oncology</b>				
Nerlynx®	Puma	HER2-positive breast cancer	Submitted	CAN
Advaxis family	Advaxis	HPV-associated cancers and others	Phase 1 – Phase 3	CAN
<b>Other</b>				
Impavido®	N/A	Leishmaniasis	Marketed	Global <sup>2</sup>
Tenapanor	Ardelyx	Hyperphosphatemia	Phase 3	CAN
Arakoda™	60P	Prevention of malaria	Pending submission	CAN, ISR, RUS, LATAM <sup>3</sup>
60P family		Other tropical diseases	Phase 2 – Pending submission	

<sup>1</sup> Legend: **CAN**: Canada, **ISR**: Israel, **ROM**: Romania, **RUS**: Russia, **ZAF**: Sub-Saharan Africa

<sup>2</sup> Approved in Germany, Israel and the U.S. (Distributed by Profounda in the U.S.)

<sup>3</sup> Select products only for LATAM



# Consumer Products & Medical Devices

Product / Family	Licensors	Description / Indication	Status in Territory	Territory Rights <sup>1</sup>
Neuragen®	N/A	Pain associated with diabetic and peripheral neuropathy	Marketed <sup>2</sup>	Global (Ex. U.S.)
Synergy family	Synergy	Various consumer health products	Marketed	CAN, ISR, ROM, RUS, ZAF
FLEXISEQ™	Pro Bono Bio	Pain and joint stiffness associated with osteoarthritis	Submitted	QUE, ISR
Crescita family	Crescita	Dermo-cosmetic products lines	Not Yet Marketed	CAR, ISR, ROM, RUS, ZAF
TULSA-PRO®	Profound	Prostate ablation	Pending submission	CAN

<sup>1</sup> Legend: **CAN**: Canada, **CAR**: the Caribbean, **ISR**: Israel, **QUE**: Quebec, **ROM**: Romania, **RUS**: Russia, **ZAF**: Sub-Saharan Africa

<sup>2</sup> Approved and marketed in Canada and the UAE